Lack of vincristine-cyclophosphamide potentiation in different experimental tumour lines
article
Combination chemotherapy with vincristine and cyclophosphamide was investigated in the L1210 leukaemia, the Lewis lung carcinoma, the mouse C22LR osteosarcoma and in two experimental colon tumour lines. Therapeutic synergism could not be demonstrated in any of the tumour cell lines. In the L1210 experiments, simultaneous treatment resulted in therapeutic antagonism. This less than additive effect could be avoided by using scheduling with a time interval of at least 12hr. The sequence in which the two drugs were administered did not influence the results. Studies on haemopoietic stem cells showed an additive effect in all of the schedules investigated. It seems preferable to treat L1210 leukaemia and possibly other rapidly proliferating neoplastic lines by a sequential application of vincristine and cyclophosphamide, not because of any potentiating effect but because drug antagonism can be circumvented in this way.
TNO Identifier
354035
Source
European Journal of Cancer, 15(4), pp. 499-507.
Pages
499-507
Files
To receive the publication files, please send an e-mail request to TNO Repository.